Elusys Therapeutics is a privately-held organization specializing in the advancement of antibody treatments for infectious illnesses. For more than a decade, Elusys has been actively involved in creating innovative therapies for managing exposure to anthrax subsequent to a natural occurrence or deliberate dissemination of anthrax spores. The company’s executive team possesses substantial expertise in the late-stage development of biological drugs as well as in obtaining and overseeing government agreements that facilitate drug development. Since 2002, Elusys has been awarded in excess of $240 million in development subsidies and contracts from the Biomedical Advanced Research and Development Authority (BARDA).